Summary. In order to verify whether or not insulininduced blood glucose control can acutely lower glycosylated haemoglobin levels, HbA I (a+b+c) (HbAI) was measured in 11 diabetics before, during and after 3 days of treatment with an "artificial endocrine pancreas" (Biostator). Initially 5 patients were in fair glycaemic control (group A), while the other 6 showed poor control (group B). HbAI levels decreased significantly after 3 days in both groups A (from 9.6 + 0.2% to 8.5 + 0.3%, mean + SEM, p < 0.05) and B (from 13.7 + 0.2% to 12.6 + 0.3%, p < 0.05). A further HbAI decrease was observed until day 60 following Biostator treatment, during which period glycaemic control inproved, as assessed by fasting and post-lunch plasma glucose values and daily glycosuria determined every 10 days.
The total glycosylated haemoglobin (HbAI) level in poorly controlled diabetics is markedly increased in comparison with normal and diabetic subjects in good control [1, 2] . It shows good correlation with various indices of glycaemic control [3] . It is generally accepted that HbAI constitutes a useful guide to diabetes management [4, 5] and routine simultaneous determination of HbAI and blood glucose in diabetics has been proposed [6] .
At present, it is well known that the HbAI levels decrease slowly after several weeks of improved glycaemic control in diabetics [3, 7, 8, 9, 10] . Few results are, however, available concerning changes in HbAI in the course of short-term blood glucose variations in diabetic patients [11, 12] , although many studies relating the rapidity of the Hb glycosylation process to the ambient glucose concentration have been reported in vitro [13, 14, 15] . Thus, it is not presently known whether acute therapeutic manipulation of blood glucose levels significantly affects HbAI concentrations.
We have therefore investigated HbAI levels in eleven diabetics before, during and after three days of glucose controlled insulin infusion using a so-called "artificial endocrine pancreas" (GCIIS).
Materials and Methods

Patients and Protocol
Eleven diabetics were recruited for the study after full explanation of its methods and purposes. Their clinical features are shown in Table 1 . The patients were not taking any therapy other than insulin, except for case 2, who was given only oral hypoglycaemic agents. In each patient plasma glucose (fasting and 90 min postlunch) was determined at least twice in the month before admission at fortnightly intervals. A glycaemic profile (plasma glucose concentration measured fasting, post-breakfast, pre-and postlunch, pre-and post-dinner, and at bed-time), and daily glycosuria were determined in all patients soon after hospitalization. The mean daily plasma glucose level was also calculated. Since therapy was not changed when patients entered the hospital, the results were taken to reflect the degree of control before admission.
Patients were divided in two groups according to the degree of their glycaemic control. Group A consisted of 5 diabetics with fair control (plasma glucose: fasting less than 150 mg/100 ml, postlunch less than 200mg/100ml, mean daily less than 170mg/ 100 ml; glycosuria less than 15 g/24 h). Group B consisted of 6 diabetics in poor control (plasma glucose: fasting more than Plasma and urinary glucose levels were determined with a Beckman Glucose Analyzer.
Analysis of variance (ANOVA) was used to assess differences of HbAI levels before, during and after GCIIS therapy and during 
Results
Blood glucose decreased to the normal range in all patients after a few hours [1 to 4] of GCIIS treatment and remained continuously controlled both during fasting (80-110 mg/100 ml) and post-lunch (120-140mg/100ml). No significant changes in haematocrit, haemoglobin, red blood cell and reticulocyte count were observed after 72 h blood withdrawal by GCIIS for continuous glucose monitoring. Glycaemic control improved in each patient during appropriate subcutaneous insulin therapy following GCIIS treatment as assessed by fasting and post-lunch plasma glucose values and daily glycosuria (Table 2) .
On admission HbAI levels were markedly increased in all patients in comparison with normal subjects (11.8 + 0.7% vs 6.4 + 0.1%, mean _+ SEM, p < 0.001) and showed significant correlations with fasting (r = 0.65, p < 0.01), post-lunch (r = 0.57, p < 0.05) and mean daily (r = 0.61, p < 0.05) plasma glucose values (Fig. 1) . HbAI levels were higher in diabetics with poor glycaemic control than in diabetics in fair control (13.7 _+ 0.2% vs 9.6 + 0.2% of groups B and A, respectively; p < 0.001).
Changes in HbAI levels in the course of three days normoglycaemia achieved with the GCIIS and thereafter up to day 150 after Biostator treatment are summarized in Table 3 . After 24 and 48 h of GCIIS treatment no statistically significant difference was present in HbAI levels. In contrast, HbAI decreased significantly after 72 h from 9.6 _+ 0.2% to 8.5 _+ 0.3% in group A and from 13.7 + 0.2% to 12.6 _+ 0.3% in group B (p < 0.05 in both groups). The mean HbAI level decrease was about 1% in the two groups (11% decrease in group A and 8% in B, HbAI basal value being taken as 100%). The decrease of glycosylated haemoglobin (dependent variable) during 72 h of GCIIS control (independent variable) was confirmed by the significant linear regression slope (group A: p < 0.025; group B: p < 0.01). The HbAI improvement continued after stopping GCIIS and changing to appropriate subcutaneous insulin therapy (Fig. 2) . In group B HbAI levels showed a significant decrease vs day 3 of GCIIS control on day 20 of conventional treatment (p < 0.01). A further HbAI decrease was observed until day 60.
Discussion
It is now well established that increased HbAI levels represent a post-synthetic effect of chronic hyperglycaemia [22] . HbAI shows a significantly lower level in poorly controlled diabetics after 3-4 weeks of subcutaneous appropriate insulin treatment [3, 8, 9] or 2 weeks treatment with a portable insulin-infusion pump [10] . Recently we observed a significant decrease in HbAI in five untreated diabetics on the 10th day of conventional insulin treatment with a more marked fall in the following weeks [7] . It, therefore, seems likely that the HbAI level decreases only after several days or weeks of improved glycaemic control and that it represents an index of mean blood glucose value over a period of many weeks before examination [5] .
Extensive results of short-term effects of appropriate insulin treatment on the Hb glycosylation process have not been described in diabetics. However, a careful investigation of this problem necessarily implies preliminary methodological considerations.
Firstly, diabetics must be carefully selected so that fixed HbAI levels are demonstrated for several days before the start of investigation. Secondly, an accurate and highly reproducible method for determination of glycosylated haemoglobin is mandatory. Thirdly, and perhaps more difficult to realize, a suitable index of glycaemic control following appropriate insulin therapy must be considered.
In our study the first and second criteria were met, while the third was attempted using a glucose controlled insulin infusion system. Under these conditions we observed a slight, but progressive decrease in HbAI levels in diabetics, previously in either poor or fair glycaemic control, in the course of three days of GCIIS therapy. The results suggest that some metabolic consequences of diabetic hyperglycaemia, such as enhanced HbAI levels, may be reversed early by strict control of blood glucose values during a three day period and they confirm our recent observation of a significant HbAI decrease in four untreated diabetics after 48 h of GCIIS therapy [11] .
The mean HbAI decrease during GCIIS treatment was about 1% in both groups. This rapid change requires explanation. The mean red blood cell renewal in the course of three days accounts for about 2.5% of the total circulating erythrocytes in normal subjects and thus only 2.5% of total haemoglobin will be synthesized in this period. In the hypothetical condition of absent or markedly reduced glycosylation rate, a HbAI decrease should be observed equal to 9.6% (group A) or 13.7% (group B) of the renewed haemoglobin, that is 0.3-0.4% of total glycosylated haemoglobin after 3 days. On the other hand it has been recently demonstrated that erythrocyte half-life as measured by 51Cr labelling is reduced in diabetics with poor glycaemic control [23] . Thus the Hb renewal rate should be more rapid in these patients than in normals and might explain, at least in part, the difference between hypothetically expected and observed HbAI decrease during GCIIS treatment. Acute blood withdrawal was probably of little importance in this regard, based on the reticulocyte count and other haematological parameters, which did not significantly change before and after GCIIS treatment. Moreover, although the iron kinetic data of Bunn et al. [22] show that the HbAI non-enzymatic glycosylation process is slightly reversible in vivo, the 3 days HbAI de-glycosylation percentage is very small and it would be hard to calculate a quantitative estimate of the HbAI de-glycosylated fraction over this period [24] . Therefore it does not seem possible to consider the HbAI decrease during GCIIS treatment as a consequence of fast de-glycosylation process, as recently proposed by Svendsen et al. [12] , whose hypothesis is in sharp contrast with many in vitro and in vivo results [22, 11, 25, 26] .
In our patients the HbAI decrease continued until day 60 after GCIIS treatment during conventional but carefully designed insulin therapy. This result agrees with the idea that haemoglobin is glycosylated very slowly, continuously, and nearly irreversibly during the entire life span of the red blood cell [22] . The HbAI decrease in poorly controlled diabetics confirms previous reports [3, 7, 8, 9, 10] and is a tangible proof of reversibility of a biological abnormality following chronic hyperglycaemia. A significant HbAI decrease, however, was observed even in diabetics initially in fair control, confirming that in these patients also HbAI is a reliable indicator of the improved control achieved with more appropriate insulin therapy. We conclude that the HbAI level not only reflects the long-term effects of previous glycaemic control in diabetics, but is also sensitive to recent acute variations in mean blood glucose levels, as those realized during GCIIS treatment.
